Equities research analysts expect Henry Schein, Inc. (NASDAQ:HSIC) to announce sales of $2.64 billion for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Henry Schein’s earnings. The lowest sales estimate is $2.61 billion and the highest is $2.67 billion. Henry Schein posted sales of $3.38 billion during the same quarter last year, which would indicate a negative year over year growth rate of 21.9%. The business is scheduled to report its next earnings report on Wednesday, February 19th.
According to Zacks, analysts expect that Henry Schein will report full year sales of $9.95 billion for the current financial year, with estimates ranging from $9.93 billion to $9.99 billion. For the next fiscal year, analysts forecast that the firm will report sales of $10.30 billion, with estimates ranging from $10.26 billion to $10.38 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Henry Schein.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, November 5th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.04. Henry Schein had a return on equity of 15.93% and a net margin of 4.66%. The firm had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.52 billion. During the same quarter in the prior year, the firm posted $1.03 earnings per share. The company’s quarterly revenue was up 6.5% on a year-over-year basis.
Several research analysts recently weighed in on HSIC shares. Cleveland Research reissued a “hold” rating on shares of Henry Schein in a research note on Friday, November 1st. TheStreet raised shares of Henry Schein from a “c+” rating to a “b” rating in a research note on Monday, October 14th. Bank of America increased their target price on shares of Henry Schein from $69.00 to $71.00 and gave the stock a “neutral” rating in a report on Tuesday. Piper Jaffray Companies lifted their price target on shares of Henry Schein from $72.00 to $80.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Finally, BidaskClub raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Wednesday, November 27th. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $72.08.
Henry Schein stock opened at $69.42 on Friday. The company has a current ratio of 1.63, a quick ratio of 0.92 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $10.15 billion, a P/E ratio of 16.81, a PEG ratio of 2.71 and a beta of 0.84. The business has a 50-day moving average of $66.70 and a 200-day moving average of $65.85. Henry Schein has a 1 year low of $56.58 and a 1 year high of $72.81.
Henry Schein announced that its board has initiated a share repurchase program on Thursday, October 31st that allows the company to buyback $400.00 million in shares. This buyback authorization allows the company to repurchase up to 4.3% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.
In other Henry Schein news, SVP Michael S. Ettinger sold 3,671 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $66.96, for a total transaction of $245,810.16. Following the completion of the transaction, the senior vice president now owns 87,972 shares in the company, valued at approximately $5,890,605.12. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Vice Chairman James P. Breslawski sold 6,856 shares of Henry Schein stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $66.96, for a total value of $459,077.76. Following the completion of the sale, the insider now directly owns 242,190 shares in the company, valued at approximately $16,217,042.40. The disclosure for this sale can be found here. Insiders have sold a total of 123,655 shares of company stock worth $8,373,585 over the last 90 days. Corporate insiders own 1.06% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Arizona State Retirement System grew its holdings in shares of Henry Schein by 2.0% during the second quarter. Arizona State Retirement System now owns 77,119 shares of the company’s stock worth $5,391,000 after buying an additional 1,494 shares in the last quarter. Advisor Partners LLC boosted its position in Henry Schein by 11.1% during the 2nd quarter. Advisor Partners LLC now owns 4,568 shares of the company’s stock worth $319,000 after acquiring an additional 458 shares during the last quarter. Financial Gravity Wealth Inc. boosted its position in Henry Schein by 168.6% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,002 shares of the company’s stock worth $70,000 after acquiring an additional 629 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Henry Schein by 0.7% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 607,834 shares of the company’s stock worth $42,488,000 after acquiring an additional 4,048 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Henry Schein by 349.6% during the 2nd quarter. SG Americas Securities LLC now owns 27,985 shares of the company’s stock worth $1,956,000 after acquiring an additional 21,760 shares in the last quarter.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Article: Momentum Indicators
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.